Improving Outcomes for Patients with Myelofibrosis: A Case-based Analysis
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.
Release Date: January 23, 2023
Expiration Date: January 23, 2024
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
Three JAK inhibitors are now approved for the treatment of intermediate- to high-risk MF with trials demonstrating improvement in spleen volume, disease symptoms, and quality of life. However, at the same time, data shows that there is a high frequency of discontinuation because of either adverse events or, more frequently, progressive disease that lead to poor outcomes with survival after ruxolitinib discontinuation. The faculty will review the clinical practice considerations for the use of new second-line therapies for the treatment of myelofibrosis and touch on data emerging from clinical trials in the second-line setting. In this presentation, Dr. Mascarenhas and Dr. Kurtin review a series of case scenarios to demonstrate selecting the most appropriate treatment for specific patient populations from the available options. Additionally, these experts share recommendations for shared decision-making and the importance of patient education.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurse practitioners, pharmacists and other allied healthcare professionals who provide care to patients with myelofibrosis.
Upon completion of this educational activity, participants should be able to:
- Align patient presentation and symptomatology with second-line options in MF through a series of case scenarios
- Outline importance and role of shared decision-making and patient/caregiver education in the treatment of MF
Improving Outcomes for Patients with Myelofibrosis: A Case-based Analysis – John O. Mascarenhas, MD and Sandra Kurtin, PhD, ANP-C, AOCN, FAPO
Instructions for Participation and Credit
This activity is eligible for credit through January 23, 2024. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and NCPD may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
John O. Mascarenhas, MD
Professor of Medicine
Tisch Cancer Institute, Division of Hematology/Oncology
Icahn School of Medicine at Mount Sinai
New York, New York
Dr. John Mascarenhas is an Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai (ISMMS) and a member of the Tisch Cancer Institute in New York City. He is the Director of the Adult Leukemia Program and Leader of Clinical Research within the Myeloproliferative Disorders Program at Mount Sinai. As a clinical investigator in malignant hematology with a focus in translational research involving myeloproliferative neoplasms (MPNs), he is primarily responsible for the clinical trials portion of the Myeloproliferative Disorders Program at ISMMS. Dr. Mascarenhas is also the principal investigator (PI) of the clinical trials project within the National Cancer Institute sponsored Myeloproliferative Neoplasms Research Consortium (MPN-RC). He has served as PI or study chair of multiple investigator-initiated and industry-sponsored early- and late-phase clinical trials evaluating innovative approaches to the treatment of MPNs and secondary leukemia.
Sandra Kurtin, PhD, ANP-C, AOCN, FAPO
Assistant Professor of Clinical Medicine
Adjunct Clinical Assistant Professor of Nursing
The University of Arizona College of Medicine
Director of Advanced Practice
Hematology/Oncology Nurse Practitioner
The University of Arizona Cancer Center
Dr. Sandra Kurtin received her BSN, MS in oncology nursing, post-graduate certification in geriatric and adult practice, and most recently, her PhD in nursing at the University of Arizona. She is an Assistant Professor of Clinical Medicine and Adjunct Clinical Assistant Professor of Nursing at The University of Arizona College of Medicine and is a Director of Advanced Practice and a Hematology/Oncology Nurse Practitioner at The University of Arizona Cancer Center.
Dr. Kurtin is a founding board member and president of the Advanced Practitioner Society for Hematology and Oncology (APSHO), as well as a member of American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), American Academy of Nurse Practitioners (AANP), and Oncology Nursing Society (ONS). In addition, she is a member of the executive committee, board of directors and co-chair of the Nursing Leadership Board for the MDS Foundation. Dr. Kurtin is associate editor for The Journal of the Advanced Practitioner in Oncology and is an editorial board member for JCO Clinical Cancer Informatics, ASH News, The Clinical Journal of Oncology Nursing, and the ASCO People Living with Cancer website. She has presented numerous regional, national, and international lectures on oncology related topics and has published numerous articles in peer-reviewed journals including the New England Journal of Medicine, Cancer Nursing, Clinical Leukemia, Blood, Leukemia Research, The Journal of the Advanced Practitioner in Oncology, and The Clinical Journal of Oncology Nursing. Dr. Kurtin’s research focus is on heath technology engagement and communicative health literacy aimed at improving health self-management among older adult cancer survivors and their caregivers.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME).
The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The University of Texas MD Anderson Cancer Center is accredited with distinction as a provider of Nursing Continuing Professional Development by The American Nurses Credentialing Center’s Commission on Accreditation.
The University of Texas MD Anderson Cancer Center designates this live activity and will award 0.50 Nursing Continuing Professional Development (NCPD) contact hours.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.50 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-23-003-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
As an organization accredited by the Accreditation Council for Pharmacy Education (ACPE), MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company.
Dr. John Mascarenhas has relevant financial relationships related to consulting from AbbVie Inc., Bristol Myers Squibb Company, Celgene Corporation ‒ A Bristol Myers Squibb Company, Constellation Pharmaceuticals, CTI BioPharma Corp., F. Hoffmann-La Roche Ltd, Incyte Corporation, Galecto Biotech, GlaxoSmithKline plc, Geron, Imago BioSciences, Kartos Therapeutics, Inc., Novartis AG, PharmaEssentia Corporation, and Sierra Oncology, Inc. He serves on the Data and Safety Monitoring Board (DSMB) for Karyopharm Therapeutics.
Dr. Sandra Kurtin has relevant financial relationships related to consulting from AbbVie Inc., Amgen Inc., AstraZeneca, Bristol Myers Squibb Company, Epizyme, Inc., GlaxoSmithKline plc, Incyte Corporation, Pharmacyclics, Inc., and Takeda Oncology.
All of the relevant financial relationships listed for these individuals have been mitigated.
Unapproved Product UseThis educational activity may contains discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.
Planning Committee Disclosures
The following planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
MediCom Worldwide, Inc.: Joan Meyer, RN, MHA, Executive Director, and Andrea Mathis, Project Manager
The University of Texas MD Anderson Cancer Center: Tamara Greiner, MA, Associate Director, and Danya Garner, MSN, Associate Director, CPE
Peer Reviewer Disclosure
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
If you have any questions or concerns regarding the content of this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242, x 114 or email us at [email protected]
Provided by The University of Texas MD Anderson Cancer Center and MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol Myers Squibb, CTI BioPharma Corp. and Sierra Oncology.
©2023 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.